Catalyzing Cigarette Smoking Cessation Through Harm Reduction Sampling Among People Unmoti
This study aims to investigate harm-reduction sampling in a choice format versus medicinal nicotine sampling on smoking behavior, identify mechanisms of sampling's effects, and explore moderators of these effects among a national sample of people unmotivated to quit smoking. Participants will be randomized 2:1 to choos
| Condition(s) | Cigarette Smoking, Tobacco Use, Cigarette Smoking Behavior |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | This study aims to investigate harm-reduction sampling in a choice format versus medicinal nicotine sampling on smoking behavior, identify mechanisms of sampling's effects, and explore moderators of these effects among a national sample of people unmotivated to quit smoking. Participants will be randomized 2:1 to choose one of two harm-reduction products (ECIG, ONP) versus a medicinal nicotine control condition (nicotine patch + lozenge, NPL), receive a 4-week starter product regimen, and then be followed for 6 months to assess use behavior. |
| Who can participate | Inclusion Criteria: 1. Able to communicate fluently in English (i.e., speaking, writing, and reading) 2. Male and female smokers who are \> 21 years of age and self-report smoking at least 5 cigarettes (menthol and/or non-menthol) per day for at least the last 6 months. 3. Have a carbon monoxide (CO) greater than or equal to 10 ppm 4. Not using any forms of nicotine regularly other than cigarettes. 5. Not interested in quitting smoking in the next 30 days. 6. Capable of giving written informed consent, including compliance with the requirements and restrictions listed in the combined consent and HIPAA form Exclusion Criteria: Smoking Behavior 1. Regular use of nicotine-containing products other than cigarettes (e.g., chewing tobacco, snuff, snus, cigars, e-cigs, IQOS, ONPS, etc.). 2. Curre |
| Ages | 21 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | Abramson Cancer Center at Penn Medicine |
| Locations | Philadelphia, Pennsylvania, United States |
| Start date | 2026-01-12 |
| NCT ID | NCT07199517 |
| Official listing | https://clinicaltrials.gov/study/NCT07199517 |